Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics Q3 revenue up 52% to $259.7 million; net loss $12.9 million

Positive Impact 3 of 5 earnings Written later

Axsome Therapeutics reported third quarter 2026 total revenue of $259.7 million, up 52% from $171.0 million a year earlier, and a net loss of $12.9 million, or $(0.25) per share, versus $47.2 million, or $(0.94) per share, in the prior-year quarter. Operating costs rose, with SG&A expenses of $203.1 million compared with $150.2 million, and the company said its current cash is sufficient to fund operations into cash flow positivity.

Key points

  • Total revenue was $259.7 million for Q3 2026, versus $171.0 million in Q3 2025; AUVELITY net product sales were $207.6 million, up 53%.
  • Net loss narrowed to $12.9 million, or $(0.25) per share, from $47.2 million, or $(0.94) per share; the loss includes $26.4 million in stock-based compensation.
  • SG&A expenses rose to $203.1 million from $150.2 million, and R&D expenses rose to $50.6 million from $40.2 million.
  • Cash and cash equivalents were $313.9 million at September 30, 2026, compared with $322.9 million at December 31, 2025.

The filing

CompanyAxsome Therapeutics, Inc. (AXSM)
Form8-K, current report
Filed with the SECNov 2, 2026, 7:05 AM ET
Accession number0001193125-26-442628

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.